ArticleExperimental and therapeutic medicine2026
Tislelizumab-induced psoriasis in a patient with hepatocellular carcinoma: A case report.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are widely incorporated into first-line treatment regimens for advanced hepatocellular carcinoma (HCC). Nevertheless, the growing incidence of immune-related adverse events (irAEs), particularly dermatologic toxicities, poses a substantial challenge to the continuation of anticancer therapy. The present study describes a case of tislelizumab-associated psoriasis in a patient with hepatitis C virus (HCV)-related HCC, emphasizing the need for prompt recognition and individualized management. A 60-year-old man with stage IIIA HCC and chronic HCV infection developed progressively worsening erythematous plaques with scaling during the eighth cycle of tislelizumab plus bevacizumab. Histopathological examination of a skin biopsy supported a diagnosis of pustular psoriasis. A Naranjo Adverse Drug Reaction Probability Scale score of 7 suggested that tislelizumab was the probable causative agent. Because the patient had type 2 diabetes mellitus and declined systemic glucocorticoid treatment, tislelizumab was discontinued, and narrow-band ultraviolet B (NB-UVB) phototherapy was administered in combination with topical corticosteroids. The skin lesions markedly resolved with no recurrence during the 6-week follow-up period. To the best of our knowledge, this is the first report of NB-UVB phototherapy successfully treating ICI-induced psoriasis. This case underscores the need for close monitoring of cutaneous irAEs during ICI therapy and suggests that NB-UVB phototherapy may be an effective alternative to systemic corticosteroids for managing ICI-induced psoriasis, particularly in patients where preservation of antitumor immunity is desirable or systemic steroids are contraindicated. Regular multidisciplinary follow-up and individualized management of adverse events are essential for optimizing both oncological and dermatological outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.